Skip to main content

Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents.

Publication ,  Journal Article
Hornik, CP; Yogev, R; Mourani, PM; Watt, KM; Sullivan, JE; Atz, AM; Speicher, D; Al-Uzri, A; Adu-Darko, M; Payne, EH; Gelber, CE; Lin, S ...
Published in: J Clin Pharmacol
December 2019

Milrinone is a type 3 phosphodiesterase inhibitor used to improve cardiac output in critically ill infants and children. Milrinone is primarily excreted unchanged in the urine, raising concerns for toxic accumulation in the setting of renal dysfunction of critical illness. We developed a population pharmacokinetic model of milrinone using nonlinear mixed-effects modeling in NONMEM to perform dose-exposure simulations in children with variable renal function. We included children aged <21 years who received intravenous milrinone per clinical care. Plasma milrinone concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay (range 1-5000 ng/mL). We performed dose-exposure simulations targeting steady-state therapeutic concentrations of 100-300 ng/mL previously established in adults and children with cardiac dysfunction. We simulated concentrations over 48 hours in typical subjects with decreasing creatinine clearance (CrCl), estimated using the updated bedside Schwartz equation. Seventy-four patients contributed 111 plasma samples (concentration range, 4-634 ng/mL). The median (range) postmenstrual age (PMA) was 3.7 years (0-18), and median weight (WT) was 13.1 kg (2.6-157.7). The median serum creatinine and CrCl were 0.5 mg/dL (0.1-3.1) and 117.2 mL/min/1.73 m2 (13.1-261.3), respectively. A 1-compartment model characterized the pharmacokinetic data well. The final model parameterization was: Clearance (L/h) = 15.9*(WT [kg] / 70)0.75 * (PMA1.12 / (67.71.12 +PMA1.12 )*(CrCl / 117)0.522 ; and Volume of Distribution (L) = 32.2*(WT [kg] / 70). A loading dose of 50 µg/kg followed by a continuous infusion of 0.5 µg/kg/min resulted in therapeutic concentrations, except when CrCl was severely impaired at ≤30 mL/min/1.73 m2 . In this setting, a 25 µg/kg loading dose and 0.25 µg/kg/min continuous infusion resulted in therapeutic exposures.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Pharmacol

DOI

EISSN

1552-4604

Publication Date

December 2019

Volume

59

Issue

12

Start / End Page

1606 / 1619

Location

England

Related Subject Headings

  • Vasodilator Agents
  • Pharmacology & Pharmacy
  • Milrinone
  • Male
  • Infant, Newborn
  • Infant
  • Humans
  • Female
  • Creatinine
  • Child
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hornik, C. P., Yogev, R., Mourani, P. M., Watt, K. M., Sullivan, J. E., Atz, A. M., … Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee, . (2019). Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. J Clin Pharmacol, 59(12), 1606–1619. https://doi.org/10.1002/jcph.1499
Hornik, Christoph P., Ram Yogev, Peter M. Mourani, Kevin M. Watt, Janice E. Sullivan, Andrew M. Atz, David Speicher, et al. “Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents.J Clin Pharmacol 59, no. 12 (December 2019): 1606–19. https://doi.org/10.1002/jcph.1499.
Hornik CP, Yogev R, Mourani PM, Watt KM, Sullivan JE, Atz AM, et al. Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. J Clin Pharmacol. 2019 Dec;59(12):1606–19.
Hornik, Christoph P., et al. “Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents.J Clin Pharmacol, vol. 59, no. 12, Dec. 2019, pp. 1606–19. Pubmed, doi:10.1002/jcph.1499.
Hornik CP, Yogev R, Mourani PM, Watt KM, Sullivan JE, Atz AM, Speicher D, Al-Uzri A, Adu-Darko M, Payne EH, Gelber CE, Lin S, Harper B, Melloni C, Cohen-Wolkowiez M, Gonzalez D, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. J Clin Pharmacol. 2019 Dec;59(12):1606–1619.

Published In

J Clin Pharmacol

DOI

EISSN

1552-4604

Publication Date

December 2019

Volume

59

Issue

12

Start / End Page

1606 / 1619

Location

England

Related Subject Headings

  • Vasodilator Agents
  • Pharmacology & Pharmacy
  • Milrinone
  • Male
  • Infant, Newborn
  • Infant
  • Humans
  • Female
  • Creatinine
  • Child